Related Experiment Video
Updated: Sep 10, 2026
Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
Dupilumab-Associated Ocular Surface Disease in Atopic Dermatitis: A Large Prospective Cohort Study From the BioDay
Nienke Veldhuis1, Roselie E Achten1, Chantal M van Luijk2
1From the Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis (N.V., R.E.A., C.D., M.d.G., I.M.H., M.S.d.B.W.), University Medical Center Utrecht, Utrecht, The Netherlands.
Purpose:
Dupilumab-associated ocular surface disease (DAOSD) is a frequently reported side effect in atopic dermatitis (AD) patients treated with dupilumab. This study aimed to investigate the frequency and severity of DAOSD, the effect of ophthalmic treatment on (DA)OSD, and the effect of dupilumab on conjunctival goblet cells (GCs).
Design:
Prospective, monocenter cohort study PARTICIPANTS: Adult patients with moderate-to-severe AD from the BioDay registry treated with dupilumab at the University Medical Center Utrecht, the Netherlands.
Methods:
Ophthalmological and dermatological examinations were performed at baseline (start of dupilumab), week 4, and week 28, between February 2020 and January 2025. Ocular surface disease (OSD) severity was assessed using the Utrecht Ophthalmic Inflammatory and Allergic Disease score. DAOSD was defined as a ≥3-point increase in Utrecht Ophthalmic Inflammatory and Allergic Disease score from baseline. Conjunctival impression cytology was performed to study the quantity and function of conjunctival GCs.
Main Outcome Measures:
Frequency and severity of DAOSD, and the quantity and function of conjunctival GCs during dupilumab treatment.
Results:
OSD was present in 94.0% (n = 141/150) of AD patients at baseline, while only 60.0% (n = 90/150) reported ocular symptoms. During 28 weeks of dupilumab treatment, 30.7% (n = 46/150) of patients developed DAOSD. The use of ophthalmic medication increased from 15.3% (n = 23/150) at baseline to 64.7% (n = 97/150) at week 28. GC numbers remained stable between baseline and week 28, while Mucin 5AC (MUC5AC) production in Cytokeratin 19-CD45-MUC5AC+ cells significantly decreased.
Conclusions:
This study highlights the high prevalence of OSD in moderate-to-severe AD patients before dupilumab treatment. DAOSD was observed in 30.7% of patients, despite the increased use of ophthalmic treatment. While conjunctival GC numbers remain stable but low, dupilumab was associated with reduced MUC5AC expression.
